From pre-clinical development through Phase 1, 2, 3, and 4 post-market surveillance
Vaccine clinical trials are conducted in a structured sequence of phases, each designed to answer specific questions about safety, immune response, and effectiveness. No vaccine can be approved for public use without completing this process. Each phase must demonstrate acceptable safety before the next phase begins.
The full clinical trial process typically takes 10–15 years for a conventional vaccine. Accelerated timelines (such as during COVID-19) used parallel development and pre-investment — but did not skip any phase.
Before any human testing, vaccines are tested extensively in laboratory and animal studies:
Vaccine candidates are tested in cell cultures to assess whether they produce the intended immune response. Dozens of candidates may be tested; most fail at this stage.
Promising candidates are tested in animals (typically mice, then primates) to assess immune response, identify appropriate dosing, and screen for early safety signals.
If pre-clinical results are promising, the developer submits an Investigational New Drug (IND) application to the FDA. Approval of the IND allows human trials to begin.
Participants
20–100 healthy adults
Duration
1–2 years
Phase 1 trials are not designed to test effectiveness — the group is too small.
Participants
Hundreds — diverse age groups
Duration
2–3 years
Phase 2 results determine whether the vaccine produces a strong enough immune response to justify the large Phase 3 trial.
Participants
Thousands to tens of thousands
Duration
2–4 years
Phase 3 trials are the primary basis for regulatory approval. COVID-19 Phase 3 trials enrolled 30,000–44,000 participants.
Phase 4 begins after regulatory approval and continues indefinitely. It is sometimes called post-market surveillance.
Passive surveillance — anyone can report adverse events. Signal detection tool. Managed by CDC and FDA.
Active surveillance — monitors 12 million covered lives using electronic health records. Can calculate true incidence rates.
FDA's active surveillance system. Near real-time monitoring of both safety and effectiveness in tens of millions of people.
Some manufacturers conduct formal Phase 4 trials as a condition of approval — particularly for accelerated approvals or when specific populations require further study.